News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
711,917 Results
Type
Article (41824)
Company Profile (265)
Press Release (669828)
Multimedia
Podcasts (55)
Webinars (12)
Section
Business (207419)
Career Advice (2051)
Deals (35827)
Drug Delivery (99)
Drug Development (81611)
Employer Resources (173)
FDA (16379)
Job Trends (15079)
News (349772)
Policy (32878)
Tag
Academia (2673)
Academic (1)
Accelerated approval (5)
Adcomms (20)
Allergies (87)
Alliances (50818)
ALS (95)
Alzheimer's disease (1401)
Antibody-drug conjugate (ADC) (133)
Approvals (16375)
Artificial intelligence (283)
Autoimmune disease (23)
Automation (16)
Bankruptcy (361)
Best Places to Work (11808)
BIOSECURE Act (19)
Biosimilars (107)
Biotechnology (189)
Bladder cancer (79)
Brain cancer (27)
Breast cancer (291)
Cancer (2330)
Cardiovascular disease (181)
Career advice (1716)
Career pathing (30)
CAR-T (154)
Cell therapy (439)
Cervical cancer (20)
Clinical research (66386)
Collaboration (877)
Company closure (2)
Compensation (558)
Complete response letters (19)
COVID-19 (2628)
CRISPR (42)
C-suite (258)
Cystic fibrosis (101)
Data (2310)
Decentralized trials (2)
Denatured (22)
Depression (44)
Diabetes (276)
Diagnostics (6578)
Digital health (19)
Diversity (9)
Diversity, equity & inclusion (44)
Drug discovery (123)
Drug pricing (102)
Drug shortages (25)
Duchenne muscular dystrophy (97)
Earnings (87496)
Editorial (40)
Employer branding (21)
Employer resources (147)
Events (114245)
Executive appointments (753)
FDA (17756)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (781)
Gene editing (112)
Generative AI (22)
Gene therapy (315)
GLP-1 (722)
Government (4483)
Grass and pollen (4)
Guidances (150)
Healthcare (19160)
Huntington's disease (24)
IgA nephropathy (27)
Immunology and inflammation (122)
Indications (29)
Infectious disease (2774)
Inflammatory bowel disease (143)
Inflation Reduction Act (8)
Influenza (53)
Intellectual property (98)
Interviews (318)
IPO (16625)
IRA (40)
Job creations (3679)
Job search strategy (1455)
Kidney cancer (10)
Labor market (43)
Layoffs (479)
Leadership (17)
Legal (7950)
Liver cancer (77)
Lung cancer (325)
Lymphoma (156)
Machine learning (9)
Management (59)
Manufacturing (330)
MASH (73)
Medical device (13618)
Medtech (13623)
Mergers & acquisitions (19776)
Metabolic disorders (705)
Multiple sclerosis (83)
NASH (16)
Neurodegenerative disease (92)
Neuropsychiatric disorders (27)
Neuroscience (1953)
NextGen: Class of 2025 (6668)
Non-profit (4592)
Now hiring (40)
Obesity (371)
Opinion (208)
Ovarian cancer (80)
Pain (91)
Pancreatic cancer (89)
Parkinson's disease (151)
Partnered (21)
Patents (244)
Patient recruitment (116)
Peanut (47)
People (58411)
Pharmaceutical (63)
Pharmacy benefit managers (19)
Phase I (20727)
Phase II (29239)
Phase III (21747)
Pipeline (1349)
Policy (146)
Postmarket research (2577)
Preclinical (8911)
Press Release (68)
Prostate cancer (107)
Psychedelics (30)
Radiopharmaceuticals (255)
Rare diseases (385)
Real estate (6032)
Recruiting (65)
Regulatory (22587)
Reports (47)
Research institute (2425)
Resumes & cover letters (353)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (70)
Series A (133)
Series B (89)
Service/supplier (11)
Sickle cell disease (53)
Special edition (16)
Spinal muscular atrophy (150)
Sponsored (30)
Startups (3655)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (48)
The Weekly (31)
Vaccines (703)
Venture capitalists (42)
Weight loss (237)
Women's health (37)
Worklife (17)
Date
Today (35)
Last 7 days (943)
Last 30 days (3070)
Last 365 days (32769)
2025 (11835)
2024 (35625)
2023 (40575)
2022 (51675)
2021 (56277)
2020 (54840)
2019 (47547)
2018 (35740)
2017 (32701)
2016 (32117)
2015 (38225)
2014 (31855)
2013 (27020)
2012 (29209)
2011 (29902)
2010 (27893)
Location
Africa (743)
Alabama (54)
Alaska (7)
Arizona (233)
Arkansas (13)
Asia (38914)
Australia (6354)
California (6434)
Canada (2068)
China (542)
Colorado (272)
Connecticut (279)
Delaware (160)
Europe (84460)
Florida (951)
Georgia (216)
Idaho (58)
Illinois (552)
India (27)
Indiana (322)
Iowa (11)
Japan (172)
Kansas (107)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (935)
Massachusetts (4775)
Michigan (226)
Minnesota (408)
Mississippi (2)
Missouri (82)
Montana (28)
Nebraska (25)
Nevada (68)
New Hampshire (64)
New Jersey (1800)
New Mexico (29)
New York (1810)
North Carolina (1004)
North Dakota (8)
Northern California (2820)
Ohio (211)
Oklahoma (14)
Oregon (35)
Pennsylvania (1424)
Puerto Rico (13)
Rhode Island (33)
South America (1132)
South Carolina (26)
South Dakota (1)
Southern California (2422)
Tennessee (107)
Texas (957)
United States (24109)
Utah (190)
Virginia (153)
Washington D.C. (65)
Washington State (568)
West Virginia (3)
Wisconsin (57)
711,917 Results for "integral molecular inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Collaboration
Lilly Hops On Hot Molecular Glue Train With $1.2B+ Magnet Deal
The molecular glue space has attracted several Big Pharma players over the past few years, including Novo Nordisk, Pfizer and Novartis.
February 28, 2025
·
2 min read
·
Tristan Manalac
Business
Integrated DNA Technologies and Molecular Health Ink Commercial Partnership
Genomics solutions provider Integrated DNA Technologies (IDT) and Bio-IT company Molecular Health have entered into a global multi-year agreement, starting in the U.S., to integrate their next generation sequencing (NGS) capabilities.
May 15, 2024
·
6 min read
Pharm Country
Integral Molecular Launches Virus Neutralization Assay Services to Drive Antiviral Discovery
Integral Molecular announces the launch of its Virus Neutralization Assay Services enabling researchers to rapidly obtain high-quality data to advance their vaccines and therapeutic antibodies.
April 16, 2024
·
2 min read
Lone Star Bio
Molecular Templates, Inc. Provides Interim Update
Molecular Templates, Inc. today provided an update on its clinical-stage programs.
June 3, 2024
·
7 min read
Press Releases
Meridian Bioscience Introduces New Enzyme Stabilization Services for Molecular Diagnostics
April 23, 2025
·
4 min read
Pharm Country
Integral Molecular Achieves ISO 9001 Certification for its Membrane Proteome Array Service
Integral Molecular proudly announces the achievement of IS0 9001 certification for the quality systems and processes used in its Membrane Proteome Array™ specificity testing services.
March 27, 2024
·
2 min read
Drug Development
Molecular Glue Degraders at Inflection Point as Pharma Dives In
Novartis, Biogen, Takeda and Novo Nordisk are all betting on advances in the molecular glue degraders space, collectively investing billions in hopes of treating cancer, Alzheimer’s disease, cardiometabolic disease and more.
December 16, 2024
·
6 min read
·
Kate Goodwin
Press Releases
Healthcare Integrated Technologies Inc. Announces Corporate Name Change to SafeSpace Global Corporation and Ticker Symbol Update
April 24, 2025
·
2 min read
Business
Integral Molecular Enters Into Exclusive Antibody License With Seismic Therapeutic
Integral Molecular, a leading biotech company specializing in antibody discovery against undruggable protein targets, announced today that it has entered into an antibody license agreement with Seismic Therapeutic.
January 4, 2024
·
2 min read
Press Releases
Labcorp Launches Molecular Residual Disease and Liquid Biopsy Solutions
April 24, 2025
·
4 min read
1 of 71,192
Next
